Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCA000585

Other · developed by Incyte

Phase 2 Most advanced trial
INCY Developer
1 Registered trials

What is INCA000585?

INCA000585 is the study code for tafasitamab, given intravenously at protocol-defined timepoints in a trial in immune thrombocytopenia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Hematology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07104565 Phase 2 Immune Thrombocytopenia Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Immune Thrombocytopenia

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCA000585

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.